7SS logo

Brii Biosciences DB:7SS Stock Report

Last Price

€0.22

Market Cap

€168.8m

7D

4.7%

1Y

49.3%

Updated

06 May, 2025

Data

Company Financials +

Brii Biosciences Limited

DB:7SS Stock Report

Market Cap: €168.8m

7SS Stock Overview

Engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. More details

7SS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Brii Biosciences Limited Competitors

Heidelberg Pharma

XTRA:HPHA

€144.5m

Formycon

XTRA:FYB

€418.5m

Biotest

XTRA:BIO3

€1.4b

2invest

XTRA:2INV

€68.9m

Price History & Performance

Summary of share price highs, lows and changes for Brii Biosciences
Historical stock prices
Current Share PriceHK$0.22
52 Week HighHK$0.34
52 Week LowHK$0.096
Beta1.51
1 Month Change3.70%
3 Month Change73.64%
1 Year Change49.33%
3 Year Change-75.11%
5 Year Changen/a
Change since IPO-89.41%

Recent News & Updates

Recent updates

Shareholder Returns

7SSDE BiotechsDE Market
7D4.7%1.8%2.5%
1Y49.3%-13.8%13.4%

Return vs Industry: 7SS exceeded the German Biotechs industry which returned -14.9% over the past year.

Return vs Market: 7SS exceeded the German Market which returned 15% over the past year.

Price Volatility

Is 7SS's price volatile compared to industry and market?
7SS volatility
7SS Average Weekly Movement20.3%
Biotechs Industry Average Movement5.9%
Market Average Movement6.4%
10% most volatile stocks in DE Market12.9%
10% least volatile stocks in DE Market3.1%

Stable Share Price: 7SS's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 7SS's weekly volatility has increased from 13% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201798Zhi Hongwww.briibio.com

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease.

Brii Biosciences Limited Fundamentals Summary

How do Brii Biosciences's earnings and revenue compare to its market cap?
7SS fundamental statistics
Market cap€168.83m
Earnings (TTM)-€61.90m
Revenue (TTM)€6.70m

25.2x

P/S Ratio

-2.7x

P/E Ratio

Is 7SS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7SS income statement (TTM)
RevenueCN¥54.99m
Cost of RevenueCN¥0
Gross ProfitCN¥54.99m
Other ExpensesCN¥563.15m
Earnings-CN¥508.16m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin100.00%
Net Profit Margin-924.08%
Debt/Equity Ratio0.7%

How did 7SS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 10:55
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Brii Biosciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangbin ZhouChina International Capital Corporation Limited
Xiao Wei LinEverbright Securities Co. Ltd.
Geoffrey PorgesLeerink Partners LLC